RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a fourth independent Data Safety Monitoring Board (DSMB) safety review. […]
Day: April 10, 2021
Copan, putting Covid-19 challenges behind and setting up for the post-pandemic scenario
With an email to the main distributors, Copan group’s CEO describes how the ramp-up of Covid-19-related products has been concluded, and how the company is now reorganizing to face post-pandemic challenges. Last Tuesday, Copan partners received an email signed by Copan’s CEO Stefania Triva herself. Certainly, it was not the first email […]